Latest Breaking News On - Vp market development - Page 1 : vimarsana.com

Lot Lines: The Commercial Real Estate Council (CREC) of OKC

Aeris' Global Intelligent IoT Network Supports M Auto's African Expansion to Become the Largest e-vehicle Company on the Continent

SAN JOSE, CA – October 5, 2022 – Aeris, a leading global Internet of Things (IoT) solutions provider, today announced that M Auto, the leading provider ...

IoT network to support African e-vehicle rollout

M Auto, a leading provider of electric mobility solutions in Africa, says it is utilizing secure, intelligent IoT connectivity from Aeris, a global IoT solutions provider, to help enable sustainable transportation across the continent.

Bladon Micro Turbine Signs Multi Year Partnership with Jubaili Bros

Bladon Micro Turbine (“Bladon”), the pioneer in the design, development, engineering and manufacture of micro turbine gensets (“MTGs”), has signed a multi-country distribution partnership agreement with global power solutions provider Jubaili Bros.

Polyacetal Filament Delivers Formaldehyde-free 3D-Printing Capability

Vesalio Receives Peripheral FDA 510k Clearance and Additional CE Approval

Vesalio Receives Peripheral FDA 510k Clearance and Additional CE Approval Nashville, TN, January 28, 2021 --(PR.com)-- Vesalio reports it has obtained an FDA 510k clearance and its 4th CE approval. The FDA 510k indication is for the removal of thrombi in peripheral blood vessels. The new CE approval expands the NeVa™ neuro-thrombectomy portfolio. Vesalio’s Drop Zone(TM) technology, designed to remove the full spectrum of clots from vascular anatomy, has been acclaimed for consistently achieving high first-pass rates, a key parameter associated with better patient outcomes in stroke. “The FDA 510k clearance milestone starts a new chapter for Vesalio as it expands our portfolio into additional thrombectomy market segments. In addition, we are pleased to have received a 4th CE approval that expands our neuro-vascular thrombectomy platform,” remarked Steve Rybka, CEO. “Our focus has been on stroke where NeVa is proving to be the market leader in first-pass clot removal. While we remain dedicated to advancements in stroke treatment globally, we are also employing our core technology competency to extend our therapeutic footprint.”